672 related articles for article (PubMed ID: 19071236)
1. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
Garnero P; Schott AM; Prockop D; Chevrel G
Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
[TBL] [Abstract][Full Text] [Related]
2. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations.
Rousseau JC; Chevrel G; Schott AM; Garnero P
Bone; 2010 Apr; 46(4):897-900. PubMed ID: 20005316
[TBL] [Abstract][Full Text] [Related]
3. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
4. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
[TBL] [Abstract][Full Text] [Related]
5. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta.
Rauch F; Lalic L; Roughley P; Glorieux FH
J Bone Miner Res; 2010 Jun; 25(6):1367-74. PubMed ID: 19929435
[TBL] [Abstract][Full Text] [Related]
6. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations.
Roschger P; Fratzl-Zelman N; Misof BM; Glorieux FH; Klaushofer K; Rauch F
Calcif Tissue Int; 2008 Apr; 82(4):263-70. PubMed ID: 18311573
[TBL] [Abstract][Full Text] [Related]
7. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
[TBL] [Abstract][Full Text] [Related]
8. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
9. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
10. [Biochemical markers of bone turnover. New aspect. Metabolic bone markers in osteogenesis imperfecta].
Tanaka H
Clin Calcium; 2009 Aug; 19(8):1142-7. PubMed ID: 19638698
[TBL] [Abstract][Full Text] [Related]
11. In vitro expression of osteoblastic markers in cells isolated from normal fetal and postnatal human bone and from bone of patients with osteogenesis imperfecta.
Mörike M; Schulz M; Brenner RE; Bushart GB; Teller WM; Vetter U
J Cell Physiol; 1993 Dec; 157(3):439-44. PubMed ID: 8253854
[TBL] [Abstract][Full Text] [Related]
12. Bone turnover markers in patients with osteogenesis imperfecta.
Braga V; Gatti D; Rossini M; Colapietro F; Battaglia E; Viapiana O; Adami S
Bone; 2004 Jun; 34(6):1013-6. PubMed ID: 15193547
[TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV.
Pollitt R; McMahon R; Nunn J; Bamford R; Afifi A; Bishop N; Dalton A
Hum Mutat; 2006 Jul; 27(7):716. PubMed ID: 16786509
[TBL] [Abstract][Full Text] [Related]
14. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
Cloos PA; Lyubimova N; Solberg H; Qvist P; Christiansen C; Byrjalsen I; Christgau S
Clin Lab; 2004; 50(5-6):279-89. PubMed ID: 15209436
[TBL] [Abstract][Full Text] [Related]
15. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
17. A novel RNA-splicing mutation in COL1A1 gene causing osteogenesis imperfecta type I in a Chinese family.
Xia XY; Cui YX; Huang YF; Pan LJ; Yang B; Wang HY; Li XJ; Shi YC; Lu HY; Zhou YC
Clin Chim Acta; 2008 Dec; 398(1-2):148-51. PubMed ID: 18755172
[TBL] [Abstract][Full Text] [Related]
18. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis.
Allanore Y; Borderie D; Lemaréchal H; Cherruau B; Ekindjian OG; Kahan A
J Rheumatol; 2003 Jan; 30(1):68-73. PubMed ID: 12508392
[TBL] [Abstract][Full Text] [Related]
19. A cross-sectional study of bone turnover markers in healthy premenopausal women.
de Papp AE; Bone HG; Caulfield MP; Kagan R; Buinewicz A; Chen E; Rosenberg E; Reitz RE
Bone; 2007 May; 40(5):1222-30. PubMed ID: 17331821
[TBL] [Abstract][Full Text] [Related]
20. Genetic and biochemical analyses of Israeli osteogenesis imperfecta patients.
Ries-Levavi L; Ish-Shalom T; Frydman M; Lev D; Cohen S; Barkai G; Goldman B; Byers P; Friedman E
Hum Mutat; 2004 Apr; 23(4):399-400. PubMed ID: 15024745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
